Vandetanib (ZD6474) induces antiangiogenesis through mTOR–HIF-1 alpha–VEGF signaling axis in breast cancer cells
Sign Up to like & getrecommendations! Published in 2018 at "OncoTargets and therapy"
DOI: 10.2147/ott.s175578
Abstract: Objective Vandetanib, also known as ZD6474, has recently been proved to be a clinical drug for cancer by targeting vascular endothelial growth factor receptor 2 (VEGFR2), EGFR, and RET tyrosine kinases. We hypothesized that vandetanib… read more here.
Keywords: alpha vegf; hif alpha; breast cancer; mtor ... See more keywords